Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada’s Jamp Creates Dedicated Biosimilars Division

As It Prepares To Launch Alvotech’s Higher-Strength Adalimumab Humira Rival

Executive Summary

Canada’s Jamp Pharma has delivered on plans to create a new dedicated biosimilars division as it prepares to launch the recently-approved higher-strength adalimumab biosimilar on which it has partnered with Alvotech.

You may also be interested in...



Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada

Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.

Alvotech Eyes Canada Humira Launch As Celltrion Also Bags High-Strength Approval

The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.

Alvotech And JAMP Partner On Canadian Biosimilars

Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel